What is Myriad Genetics's cancer care continuum — revenue?

Myriad Genetics (MYGN) reported cancer care continuum — revenue of $120.2M in Q1 2026.

What does cancer care continuum — revenue mean?

This metric represents the total revenue generated from diagnostic testing services and companion diagnostics focused on hereditary cancer risk assessment and oncology treatment guidance. It captures the financial performance of products designed to identify genetic predispositions and support clinical decision-making throughout the patient's cancer care journey. This segment is a primary indicator of the company's market penetration and adoption rates within the molecular oncology diagnostics sector.

Myriad Genetics (MYGN) Cancer Care Continuum — Revenue

Screener

Other product segments

Hereditary Cancer

$96.8M+2.5%

Prenatal

$44.9M0.0%

Prenatal Health

$41.9M—

Mental Health

$38.3M—

Similar metrics at other companies

HAINPersonal Care — Revenue

$12.66M-24.7%

NAKAHealth Care — Revenue

$479K-17.4%

PRGOOral Care — Revenue

$88.6M-5.4%

UHSHealth Care — Revenue

$478.5M+27.7%

UHSManaged Care — Revenue

$1.2B-2.1%

BFAMFull service center-based child care — Revenue

$557.3M+3.2%

Other financials

Income statement

See full

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

See full

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

See full

Operating cash flow-$15.7M+3.7%

CapEx$18.8M+181%

Free cash flow-$19.7M+65.1%

Valuation

See full

Market cap$310.86M-46.0%

Enterprise value$396.36M-38.7%

P/S0.4×-0.3×

Profitability

See full

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

FCF margin-17%—

Returns & leverage

See full

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Myriad Genetics’s 10-Q, filed May 6, 2026.

Filed: May 6, 2026, 6:05 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0000899923-26-000038

(in millions)	Three months ended March 31, 2026 / U.S.	Three months ended March 31, 2026 / Ro W	Three months ended March 31, 2026 / Total	Three months ended March 31, 2025 / U.S.	Three months ended March 31, 2025 / Ro W	Three months ended March 31, 2025 / Total
Cancer Care Continuum	$106.8	$13.4	$120.2	$101.4	$14.2	$115.6
Prenatal Health	41.9	—	41.9	49.2	0.1	49.3
Mental Health	38.3	—	38.3	31.0	—	31.0
Total revenue	$187.0	$13.4	$200.4	$181.6	$14.3	$195.9

Item 1. Financial Statements.

FAQ

What is Myriad Genetics's cancer care continuum — revenue?: Myriad Genetics (MYGN) reported cancer care continuum — revenue of $120.2M in Q1 2026.
What does cancer care continuum — revenue mean?: This metric represents the total revenue generated from diagnostic testing services and companion diagnostics focused on hereditary cancer risk assessment and oncology treatment guidance. It captures the financial performance of products designed to identify genetic predispositions and support clinical decision-making throughout the patient's cancer care journey. This segment is a primary indicator of the company's market penetration and adoption rates within the molecular oncology diagnostics sector.